Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752634 · ClinicalTrials.gov registry record · Phase 3
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 397
- Enrollment target
NCT01752634 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 397 participants.
The verdict
NCT01752634, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 397 participants
- Enrollment target
Study Summary
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.
Interventions
- DRUG Placebo
- DRUG Secukinumab (AIN457)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2013-04-14 |
| Est. Completion | 2019-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01752634
The ClinicalTrials.gov registry entry for NCT01752634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01752634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01752634 about?
NCT01752634 is a clinical study titled "Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis". This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additio...
What is the current status of trial NCT01752634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 397 participants. The study started on 2013-04-14. Estimated completion is 2019-01-09.
What interventions are being tested in trial NCT01752634?
The interventions under investigation include: Placebo (DRUG), Secukinumab (AIN457) (DRUG).
Who is sponsoring clinical trial NCT01752634?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.